MQV: Filler, Bone Void, Calcium Compound
What it covers
A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.
The identification in 21 CFR 888.3045, resorbable calcium salt bone void filler device. FDA gives MQV no definition of its own, so the regulation’s describes it.
FDA flags MQV devices as implants.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K262230 | Mg OSTEOREVIVE;Mg OSTEOCRETE | Bone Solutions, Inc. | Sep 11, 2026 | Traditional |
| K260364 | Device 300419 Strip | Geistlich Pharma AG | Jun 2, 2026 | Traditional |
| K252797 | JAZBI Resorbable Bone Void Filler | Sdip Innovations Pty, Ltd. | May 26, 2026 | Traditional |
| K261008 | Vitoss® BiModal Bioactive Bone Graft Substitute Foam Strip; Vitoss® BiModal Bioactive Bone Graft Substitute; Vitoss BBTrauma® Bioactive Bone Graft Substitute; Vitoss® BA2X Bioactive Bone Graft Substitute; Vitoss® Bioactive Foam Bone Graft Substitute Pack; Vitoss® Bioactive Foam Bone Graft Substitute; Vitoss® Foam Bone Graft Substitute; Vitoss® Bone Graft Substitute Filled Canister; Vitoss® Bone Graft Substitute | Stryker Spine | Apr 24, 2026 | Special |
| K253524 | Adaptos®Fuse Bone Graft | Biomendex OY | Feb 17, 2026 | Traditional |
| K253147 | FIBERGRAFT BG Putty GPS Bone Graft Substitute FIBERGRAFT BG Putty Bone Graft Substitute FIBERGRAFT AERIDYAN Matrix Bone Graft Substitute FIBERGRAFT BG Matrix Bone Graft Substitute | Prosidyan, Inc. | Oct 22, 2025 | Special |
| K251522 | Mg OSTEOINJECT; Mg OSTEOREVIVE; Mg OSTEOCRETE | Bone Solutions, Inc. | Oct 13, 2025 | Traditional |
| K252085 | Allomatrix (Allomatrix Injectable Putty; Allomatrix C; Allomatrix DR; Allomatrix Custom) | Wright Medical Technology, Inc. (Stryker Corporation) | Sep 30, 2025 | Traditional |
| K251556 | Device 300423 Granules | Geistlich Pharma AG | Jul 17, 2025 | Traditional |
| K251720 | OsteoFlo HydroFiber | SurGenTec, LLC | Jul 2, 2025 | Special |
Clearances by year
236 MQV 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 5 | 96 |
| 2025 | 14 | 57 |
| 2024 | 28 | 55 |
| 2023 | 21 | 74 |
| 2022 | 9 | 118 |
| 2021 | 8 | 88 |
| 2020 | 15 | 132 |
| 2019 | 13 | 90 |
| 2018 | 23 | 124 |
| 2017 | 17 | 124 |
| 2016 | 8 | 214 |
| 2015 | 18 | 184 |
| 2014 | 20 | 153 |
| 2013 | 12 | 197 |
| 2012 | 9 | 107 |
| 2011 | 16 | 92 |
Who submits
102 applicants cleared a MQV device since 2011. 76% of the clearances went to applicants in United States, then Netherlands (6%), United Kingdom (3%) and Taiwan (3%). By type: Traditional 85% and Special 15%.
| Applicant | Clearances since 2011 |
|---|---|
| Kuros Biosciences B.V | 11 |
| Prosidyan, Inc. | 10 |
| Novabone Products, LLC | 9 |
| Wrightmedicaltechnologyinc | 9 |
| Baxter Healthcare Corporation | 7 |
| Orthocon, Inc. | 7 |
| SeaSpine Orthopedics Corporation | 7 |
| Bone Solutions, Inc. | 6 |
How FDA classifies it
Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.
From 21 CFR 888.3045. Special controls are the requirements a 510(k) must show it meets.
Standards
21 CFR 888.3045 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent MQV clearances declared.
Ask about MQV
Questions about MQV
What is FDA product code MQV?
Product code MQV, “Filler, Bone Void, Calcium Compound” in FDA's classification database, is a Class II device type under 21 CFR 888.3045 (resorbable calcium salt bone void filler device), reviewed by FDA's Orthopedic panel. FDA's 510(k) database lists 493 clearances under MQV, 236 of them since 2011.
How many 510(k) clearances are there under MQV?
FDA’s 510(k) database listed 493 clearances under MQV as of Oct 29, 2026, 236 of them decided since 2011; the most recent decision was Sep 11, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a MQV 510(k)?
For the 28 MQV clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 93 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most MQV clearances?
Since 2011: Kuros Biosciences B.V (11), Prosidyan, Inc. (10), Novabone Products, LLC (9), Wrightmedicaltechnologyinc (9) and Baxter Healthcare Corporation (7). 102 applicants have cleared a MQV device in that time.